A Real World Evidence of Lorlatinib for Taiwanese with advanced ALK Positive Non-Small Cell Lung Cancer

被引：0

作者：

Shih, J. -Y. ^{[1
]}

Luo, Y. -H. ^{[2
]}

Chang, G. -C. ^{[3
]}

Chang, J. W. -C. ^{[4
]}

Wang, C. -C. ^{[5
]}

Yang, T. ^{[6
]}

Fang, W. ^{[7
]}

Shau, W. -Y. ^{[7
]}

机构：

[1] Natl Taiwan Univ Hosp, Taipei, Taiwan

[2] Taipei Vet Gen Hosp, Taipei, Taiwan

[3] Chung Shang Med Univ Hosp, Taichung, Taiwan

[4] Chang Gung Memory Hosp Linko, Taoyuan, Taiwan

[5] Chang Gung Mem Hosp Kaohsiung, Kaohsiung, Taiwan

[6] Taichung Vet Gen Hosp, Taichung, Taiwan

[7] Pfizer, Taipei, Taiwan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期

关键词：

real world; lorlatinib; lung cancer;

D O I：

10.1016/j.jtho.2022.07.834

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP08.02-15

引用

页码：S475 / S475

页数：1

共 50 条

[31] Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events [J].

Kilickap, Saadettin ;

Ak, Sertac ;

Dursun, Oldac U. ;

Sendur, Mehmet A. N. ;

Karadurmus, Nuri ;

Demirci, Umut .

FUTURE ONCOLOGY, 2023, 19 (29) :2003-2012

[32] Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice [J].

Passaro, Antonio ;

Lazzari, Chiara ;

Karachaliou, Niki ;

Spitaleri, Gianluca ;

Pochesci, Alessia ;

Catania, Chiara ;

Rosell, Rafael ;

de Marinis, Filippo .

ONCOTARGETS AND THERAPY, 2016, 9 :6361-6376

[33] Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer [J].

Shirish M. Gadgeel .

Current Treatment Options in Oncology, 2017, 18

[34] Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey [J].

Kilickap, S. ;

Demirci, U. ;

Bugdayci, F. ;

Tural, D. ;

Korkmaz, T. ;

Paydas, S. ;

Yilmaz, C. ;

Turna, H. ;

Sezer, A. ;

Cinkir, H. Yesil ;

Okutur, K. ;

Erman, M. ;

Eralp, Y. ;

Cabuk, D. ;

Isikdogan, A. ;

Demirkazik, A. ;

Karaoglu, A. ;

Yazilitas, D. ;

Senler, F. Cay ;

Yumuk, P. F. ;

Coskun, H. ;

Yildiz, I. ;

Oztop, I. ;

Beypinar, I. ;

Aydin, K. ;

Kaplan, M. ;

Meydan, N. ;

Olmez, O. F. ;

Ozyilkan, O. ;

Seber, S. ;

Arslan, C. ;

Sendur, M. A. ;

Cicin, I. .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) :S558-S559

[35] The Humanistic Burden of Advanced Non-Small Cell Lung Cancer Patients in Europe - A Real World Survey [J].

Taylor-Stokes, Gavin ;

Wood, Robert ;

Malcolm, Bill ;

Lees, Michael ;

Chirita, Oana .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) :S685-S685

[36] Successful treatment with lorlatinib in a patient with meningeal carcinomatosis of ALK-positive non-small cell lung cancer resistant to alectinib and brigatinib A case report [J].

Nakashima, Koki ;

Demura, Yoshiki ;

Kurokawa, Kosuke ;

Takeda, Toshihiro ;

Jikuya, Norihiro ;

Oi, Masahiro ;

Tada, Toshihiko ;

Akai, Masaya ;

Ishizuka, Tamotsu .

MEDICINE, 2021, 100 (39) :E27385

[37] A Patient-Centric, Phase II Trial of First-Line Lorlatinib&alk TKIs in China Advanced ALK plus Non-Small Cell Lung Cancer [J].

Lin, J. .

JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) :S659-S659

[38] Lung Cancer Prognostic Index Performance in US Real-World Advanced Non-Small Cell Lung Cancer Patients [J].

Shah, R. ;

John, A. ;

Alexander, M. .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) :S391-S391

[39] Clinical Data from the Real World: Efficacy of Crizotinib in Chinese Patients with Advanced ALK plus Non-Small Cell Lung Cancer and Brain Metastases [J].

Wang, Shouzheng ;

Xing, Puyuan ;

Li, Junling ;

Hao, Xuezhi ;

Zhang, Tongtong .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) :S944-S944

[40] Pharmacological and clinical properties of lorlatinib in the treatment ofALK-rearranged advanced non-small cell lung cancer [J].

Eldarsa, Haidar ;

Abdel-Rahman, Omar ;

Sangha, Randeep .

EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (13) :1547-1554

← 1 2 3 4 5 →